Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension

被引:77
作者
Castelain, V
Chemla, D
Humbert, M
Sitbon, O
Simonneau, G
Lecarpentier, Y
Hervé, P
机构
[1] Antoine Beclere Teaching Hosp, UPRES 2705, Dept Pulm Med, Clamart, France
[2] Bicetre Teaching Hosp, Cardioresp Funct Testing Unit, Le Kremlin Bicetre, France
[3] Marie Lannelongue Teaching Hosp, Dept Thorac & Vasc Surg, Le Plessis Robinson, France
关键词
primary pulmonary hypertension; prostacyclin; epoprostenol; exercise testing;
D O I
10.1164/ajrccm.165.3.2106033
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Exercise tolerance improves within a few weeks after prostacyclin initiation in patients with primary pulmonary hypertension even in the absence of significant changes in resting pulmonary vascular resistance and/or in patients who fail to respond to an acute vasodilator challenge. We tested the hypothesis that this early effect of prostacyclin may be ascribable to an improved pressure-flow response of the pulmonary circulation to exercise. Pulmonary hemodynamic variables at rest and during exercise and the 6-min walking distance were determined before and after 6 wk of continuous Intravenous prostacyclin treatment (11 +/- 1.5 ng/kg/min) in seven patients unresponsive to an acute nitric oxide vasodilator test. Mean pulmonary arterial pressure/cardiac index coordinates obtained during exercise were pooled, and the slopes of these plots were compared using covariance analysis. All hemodynamic variables at rest were unchanged after prostacyclin. By contrast, the 6-min walking distance Improved in all patients (mean increase, 81 m) and the slope of the mean pulmonary artery pressures/cardiac indexes plot decreased with prostacyclin, from 18.2 to 13.1 mm Hg/L/min/m(2) (p < 0.01). These results suggest that the improvement in exercise tolerance seen after 6 wk of prostacyclin therapy may be ascribable to a decrease in incremental pulmonary vascular resistance during exercise.
引用
收藏
页码:338 / 340
页数:3
相关论文
共 19 条
[1]   A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].
Barst, RJ ;
Rubin, LJ ;
Long, WA ;
McGoon, MD ;
Rich, S ;
Badesch, DB ;
Groves, BM ;
Tapson, VF ;
Bourge, RC ;
Brundage, BH ;
Koerner, SK ;
Langleben, D ;
Keller, CA ;
Murali, S ;
Uretsky, BF ;
Clayton, LM ;
Jobsis, MM ;
Blackburn, SD ;
Shortino, D ;
Crow, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301
[2]   SURVIVAL IN PRIMARY PULMONARY-HYPERTENSION WITH LONG-TERM CONTINUOUS INTRAVENOUS PROSTACYCLIN [J].
BARST, RJ ;
RUBIN, LJ ;
MCGOON, MD ;
CALDWELL, EJ ;
LONG, WA ;
LEVY, PS .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (06) :409-415
[3]  
BRENOT F, 1994, CHEST S, V105, P33
[4]   Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thromboembolism and primary pulmonary hypertension [J].
Castelain, V ;
Hervé, P ;
Lecarpentier, Y ;
Duroux, P ;
Simonneau, G ;
Chemla, D .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (04) :1085-1092
[5]   Matching dicrotic notch and mean pulmonary artery pressures: Implications for effective arterial elastance [J].
Chemla, D ;
Hebert, JL ;
Coirault, C ;
Salmeron, S ;
Zamani, K ;
Lecarpentier, Y .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1996, 271 (04) :H1287-H1295
[6]  
FISHMAN AP, 1985, HDB PHYSL 3, V1, P93
[7]   ROLE OF PHARMACOLOGICAL TESTS IN THE TREATMENT OF PRIMARY PULMONARY-HYPERTENSION [J].
GALIE, N ;
USSIA, G ;
PASSARELLI, P ;
PARLANGELI, R ;
BRANZI, A ;
MAGNANI, B .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (03) :A55-A62
[8]  
HIGENBOTTAM T, 1984, LANCET, V1, P1046
[9]  
HIGENBOTTAM TW, 1993, BRIT HEART J, V70, P366
[10]   Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study [J].
Humbert, M ;
Sanchez, O ;
Fartoukh, M ;
Jagot, JL ;
Le Gall, C ;
Sitbon, O ;
Parent, F ;
Simonneau, G .
EUROPEAN RESPIRATORY JOURNAL, 1999, 13 (06) :1351-1356